IBDEI2NA ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44388,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,44388,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,44388,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,44389,0)
 ;;=C91.41^^200^2228^76
 ;;^UTILITY(U,$J,358.3,44389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44389,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,44389,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,44389,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,44390,0)
 ;;=D57.01^^200^2228^78
 ;;^UTILITY(U,$J,358.3,44390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44390,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,44390,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,44390,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,44391,0)
 ;;=D57.00^^200^2228^79
 ;;^UTILITY(U,$J,358.3,44391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44391,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,44391,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,44391,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,44392,0)
 ;;=D57.02^^200^2228^80
 ;;^UTILITY(U,$J,358.3,44392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44392,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,44392,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,44392,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,44393,0)
 ;;=D68.32^^200^2228^82
 ;;^UTILITY(U,$J,358.3,44393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44393,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,44393,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,44393,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,44394,0)
 ;;=C22.2^^200^2228^83
 ;;^UTILITY(U,$J,358.3,44394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44394,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,44394,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,44394,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,44395,0)
 ;;=D58.9^^200^2228^85
 ;;^UTILITY(U,$J,358.3,44395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44395,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,44395,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,44395,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,44396,0)
 ;;=C81.99^^200^2228^86
 ;;^UTILITY(U,$J,358.3,44396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44396,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,44396,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,44396,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,44397,0)
 ;;=C81.90^^200^2228^87
 ;;^UTILITY(U,$J,358.3,44397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44397,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,44397,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,44397,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,44398,0)
 ;;=D89.2^^200^2228^88
 ;;^UTILITY(U,$J,358.3,44398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44398,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,44398,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,44398,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,44399,0)
 ;;=D05.12^^200^2228^89
 ;;^UTILITY(U,$J,358.3,44399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44399,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,44399,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,44399,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,44400,0)
 ;;=D05.11^^200^2228^90
 ;;^UTILITY(U,$J,358.3,44400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44400,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,44400,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,44400,2)
 ;;=^5001930
